Agilent Technologies (A) Shares are Up 3.28%

Agilent Technologies (A) : Traders are bullish on Agilent Technologies (A) as it has outperformed the S&P 500 by a wide margin of 4.36% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 3.35%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 3.28% in the last 1 week, and is up 7.87% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The stock has recorded a 20-day Moving Average of 4.5% and the 50-Day Moving Average is 5.79%. Agilent Technologies, Inc. is up 17.88% in the last 3-month period. Year-to-Date the stock performance stands at 15.71%.


Agilent Technologies (NYSE:A): stock turned positive on Friday. Though the stock opened at $47.49, the bulls momentum made the stock top out at $48.175 level for the day. The stock recorded a low of $47.36 and closed the trading day at $48.11, in the green by 1.26%. The total traded volume for the day was 1,881,372. The stock had closed at $47.51 in the previous days trading.

Also, Equity Analysts at the BTIG Research assumes the rating on Agilent Technologies (NYSE:A). The brokerage firm has issued a Buy rating on the shares. The Analysts at the ratings agency announces the price target to $55 per share. The rating by the firm was issued on July 22, 2016.

Agilent Technologies Inc. is engaged in the life sciences, diagnostics and applied chemical markets. The Company provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company has three business segments: the life sciences and applied markets business, the diagnostics and genomics business, and the Agilent CrossLab business. The Companys life sciences and applied markets business segment brings together the Companys analytical laboratory instrumentation and informatics. The Companys diagnostics and genomics business segment consists of three businesses: the Dako business, the genomics business and the nucleic acid solutions business. The Companys Agilent CrossLab business segment combines its analytical laboratory services and consumables business.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.